Evidence map›Paper›PMID 41514389›Full record

ArticleBMC cancer2026

Evaluating the effect of CD47 expression levels and clinicopathologic features on survival function in resected uterine carcinosarcoma: the Western Turkey example.

Murat Keser, Huseyin Salih Semiz, Ilker Cakir, Zeynep Devran Muharremoglu, Olcun Umit Unal, Baran Akagunduz, Emel Ebru Pala

Abstract read
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Murat KeserDepartment of Medical Oncology, Izmir City Hospital, 2148/11th Street, Izmir, 35540, Turkey. drmksr35@gmail.com.ORCID http://orcid.org/0000-0003-3834-0863
Huseyin Salih SemizDepartment of Medical Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-7083-8517
Ilker CakirDepartment of Obstetrics and Gynecology, Buca Seyfi Demirsoy Education and Research Hospital, Izmir, Turkey.ORCID http://orcid.org/0000-0003-0245-5298
Zeynep Devran MuharremogluSakarya Provincial Health Directorate, Presidency of Public Health Services, Sakarya, Turkey.ORCID http://orcid.org/0000-0001-8323-2277
Olcun Umit UnalDepartment of Medical Oncology, Izmir City Hospital, 2148/11th Street, Izmir, 35540, Turkey.ORCID http://orcid.org/0000-0001-7698-3574
Baran AkagunduzDepartment of Medical Oncology, Mengucek Gazi Training and Research Hospital, Erzincan, Turkey.ORCID http://orcid.org/0000-0002-4979-3123
Emel Ebru PalaDepartment of Pathology, Izmir City Hospital, Izmir, Turkey.ORCID http://orcid.org/0000-0001-7262-1867

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study is to investigate the effect of CD47 expression levels on survival function and to determine the relationship between the clinicopathological features of uterine carcinosarcoma (UCs).

methodsThe expression of CD47 was analyzed by calculating immunoreactivity scoring (IRS) which takes into account both the category of staining intensity (0: no immunostaining; 1: weak staining; 2: moderate staining; and 3: strong staining) as well as the grade of percentage of positive cells five grades ( 0 for 0%; 1 for 1–10%; 2 for 11–50%; 3, for 51–80%; and 4 for > 80%) via anti-CD47 antibodies by immunohistochemistry (IHC) in a total of 42 surgically resected tissue samples of patients with UCs. The staining intensity and percentage of positive cells were multiplied to obtain an IRS in the range of 0–12 for each case. If a case had an IRS score over 6, it is labelled as positive CD47 or vice versa. Patients’ clinicopathological parameters and survival data were documented from patient records. The survival function of patients was analyzed using Kaplan-Meier and Cox regression in univariate and multivariate analyses, respectively.

resultsThe median follow-up time was 39 (IQR = 18-74.25) and 34.50 (IQR = 14.5-73.75) months for overall survival (OS). CD47 positivity was detected in 26 of 42 (61.9%) resected UCs tissues. CD47 positivity did not have a significant effect on OS [HR = 1.03; 95% CI 0.328–3.240, p = 0.95]. Presence of relapse [HR = 5.24; 95% CI, 1.25–21.89 ,p = 0.023] and myometrial invasion being more than half [HR = 4.31; 95%CI1.16-15.94, p = 0.028] negatively affected OS, while adjuvant chemotherapy [HR = 0.16; 95% CI 0.039–0.661, p = 0.011] and radiotherapy [HR = 0.130, 95% CI 0.045–0.376, p < 0.001] had a positive effect on OS. When considering the disease-free survival (DFS), the same variables showed the same level of significance on DFS (p < 0.05).

conclusionThis study is the first to explore the potential impact of CD47 expression on survival in patients with uterine carcinosarcoma. Although CD47 status was not a significant predictor of OS or DFS, relapse, myometrial invasion, and adjuvant therapies were identified as significant survival predictors. Given the limited sample size, these findings should be interpreted with caution, and further studies with larger cohorts are warranted to clarify the potential clinical relevance of CD47 in patients with UCs. To our knowledge, this is among the few studies to investigate CD47 expression in uterine carcinosarcoma, providing preliminary evidence for its association with tumor aggressiveness.

Indexed as

Biomarkers, TumorCarcinosarcomaCD47 AntigenUterine NeoplasmsAgedFemaleHumansImmunohistochemistryKaplan-Meier EstimateMiddle AgedPrognosisTurkeyBiomarkers, TumorCD47 AntigenCD47 protein, humanCD47 proteinClinicopathologic featuresSurvival analysisUterine carcinosarcoma

Identifiers

PMID41514389
PMCPMC12888142

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.